Reviewer's report

Title: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

Version: 2 Date: 17 June 2014

Reviewer: Jennifer A Chan

Reviewer's report:

The authors have provided answers to previous questions and comments. The revised manuscript is clear and concise with excellent detail about the study findings regarding the combination of imatinib, dacarbazine, and capecitabine.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.